Stock Ratings | Wedbush lowered its price target for MetaTrader (META) to $595; Rodman initiated coverage of Actuate (ACTU) with a buy rating at $6, with upside potential of 412.82%.
TOMI Environmental Solutions, Inc. TOMZ | 0.00 | |
Viking Therapeutics, Inc. VKTX | 0.00 | |
MannKind Corporation MNKD | 0.00 | |
Actuate Therapeutics, Inc. ACTU | 0.00 | |
Bicycle Therapeutics Limited BCYC | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
HC Wainwright & Co.: Maintaining a "Buy" rating on TOMI Environmental Solutions ( TOMI Environmental Solutions, Inc.(TOMZ.US) ), while raising the price target from $3.5 to $7.
Canaccord Genuity: Maintaining a "buy" rating on Viking Therapeutics ( Viking Therapeutics, Inc.(VKTX.US) ), while raising the price target from $107 to $114.
Wells Fargo: Maintaining an "overweight" rating on MannKind ( MannKind Corporation(MNKD.US) ), while raising the price target from $11 to $14.
Rodman & Renshaw: Initial rating for Actuate Therapeutics ( Actuate Therapeutics, Inc.(ACTU.US) ) at "Buy", with a target price of $6.
Needham: Maintaining a "buy" rating on Bicycle Therapeutics ( Bicycle Therapeutics Limited(BCYC.US) ), while lowering the price target from $15 to $14.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| TOMI Environmental Solutions, Inc.(TOMZ.US) | to lift | $7.0 | $1.6 | 337.5% | HC Wainwright & Co. |
| Viking Therapeutics, Inc.(VKTX.US) | to lift | $114.0 | $33.11 | 244.31% | Canaccord Genuity |
| MannKind Corporation(MNKD.US) | to lift | $14.0 | $4.11 | 240.63% | Wells Fargo |
| LeonaBio, Inc.(LONA.US) | to lift | $18.0 | $7.29 | 146.91% | Citizens |
| uniQure N.V.(QURE.US) | to lift | $75.0 | $42.19 | 77.77% | Wells Fargo |
| Actuate Therapeutics, Inc.(ACTU.US) | Initial classification | $6.0 | $1.17 | 412.82% | Rodman & Renshaw |
| Bicycle Therapeutics Limited(BCYC.US) | cut | $14.0 | $4.01 | 249.13% | Needham |
| Intuitive Surgical, Inc.(ISRG.US) | cut | $931.0 | $352.97 | 163.76% | 汇丰 |
| Clarivate PLC(CLVT.US) | cut | $5.0 | $2.01 | 148.76% | Stifel |
| Phathom Pharmaceuticals(PHAT.US) | cut | $22.0 | $9.03 | 143.63% | Needham |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Mizuho: Upgraded Bloom Energy ( BLOOM ENERGY CORP(BE.US) ) to "Outperform Market", while lowering its price target from $285 to $242.
Barclays: Maintaining an "overweight" rating on Coca-Cola Coca-Cola Company(KO.US) stock, while raising its price target from $91 to $93.
DA Davidson: Maintaining a "neutral" rating on Starbucks Starbucks Corporation(SBUX.US) ) stock, while raising the price target from $102 to $110.
Barclays: Maintaining an "overweight" rating on Waste Management ( Waste Management, Inc.(WM.US) ), while raising the price target from $270 to $277.
First Coverage
Rodman & Renshaw: Initial rating for Actuate Therapeutics ( Actuate Therapeutics, Inc.(ACTU.US) ) at "Buy", with a target price of $6.
Deutsche Bank: Initial rating for Kymera Therapeutics ( Kymera Therapeutics, Inc.(KYMR.US) ) at "Hold", with a price target of $120.
UBS: Initial rating for SK Hynix ( SK hynix Inc. Sponsored ADR(SKHY.US) ) at "Buy", with a target price of $204.
reduction
Wells Fargo: Maintaining an "overweight" rating on Arm Holdings ( Arm Holdings(ARM.US) ), while lowering its price target from $350 to $280.
Wells Fargo: Maintaining a "Market-Similar Weight" rating for Bloom Energy ( BLOOM ENERGY CORP(BE.US) ), while lowering its price target from $217 to $176.
Goldman Sachs: Maintaining a "buy" rating on Flex Flex Ltd(FLEX.US) ) stock, while lowering its price target from $177 to $154.
Goldman Sachs: Maintaining a "buy" rating on Robinhood Markets ( Robinhood(HOOD.US) ), while lowering the price target from $137 to $118.
Wells Fargo: Maintaining an "overweight" rating on Lam Research Lam Research Corporation(LRCX.US) stock, while lowering its price target from $450 to $350.
Wedbush: Maintaining a "neutral" rating on Meta Platforms Meta Platforms(META.US) ) stock, while lowering its price target from $671 to $595.
Citigroup: Maintaining a "buy" rating on Vertiv Holdings VERTIV HOLDINGS LLC(VRT.US) ), while lowering its price target from $414 to $358.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.